NPM1 and myeloid neoplasm: A possible explanation for this finding is probably related to the fact that most patients with NPM1 myeloid neoplasm (33 out of 45 patients) were treated upfront with hypomethylating agents, and 13 of them progressed to AML at a median of 5.9 months.